Management of Antiretroviral Treatment-Related Complications

Infectious Disease Clinics of North America

Volumn 21, Issue 1, 2007, Pages 103-132

  Hoffman, Risa M ^a   Currier, Judith S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CETIRIZINE; DIDANOSINE; LAMIVUDINE; METFORMIN; NEVIRAPINE; PIOGLITAZONE; RAMIPRIL; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VIARED; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; IMMUNE RESPONSE; INSULIN RESISTANCE; LACTATE BLOOD LEVEL; LACTIC ACIDEMIA; LACTIC ACIDOSIS; LIVER TOXICITY; LONG TERM CARE; PATIENT EDUCATION; PATIENT MONITORING; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; STEVENS JOHNSON SYNDROME; VIRUS REPLICATION;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; RISK FACTORS;

EID: 34248394654     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2007.01.007     Document Type: Review

References (124)

1. Organization WH. Global access to HIV therapy tripled in past two years, but significant challenges remain. Joint News Release WHO/UNAIDS. Available at: http://www.who.int/hiv/mediacentre/news57/en/index.html. March 28, 2006.
2. Vrouenraets S.M., Treskes M., Regez R.M., et al. Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment. Antivir Ther 7 4 (2002) 239-244
3. Birkus G., Hitchcock M.J., and Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46 3 (2002) 716-723
4. Giola M., Basilico C., and Grossi P. Fatal lactic acidosis associated with tenofovir and abacavir. Int J Infect Dis 9 4 (2005) 228-229
5. James JS. d4T plus ddI: warning for pregnant women. AIDS Treat News. January 12, 2001:358:8.
6. Gerard Y., Maulin L., Yazdanpanah Y., et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 14 17 (2000) 2723-2730
7. Bonnet F., Bonarek M., Abrij A., et al. Metabolic acidosis in HIV-infected patients. Clin Infect Dis 34 9 (2002) 1289-1290
8. Moyle G.J., Datta D., Mandalia S., et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 16 10 (2002) 1341-1349
9. Laguno M., Milinkovic A., de Lazzari E., et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther 10 3 (2005) 423-429
10. Moreno A., Quereda C., Moreno L., et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther 9 1 (2004) 133-138
11. Wyles D.L., and Gerber J.G. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 40 1 (2005) 174-181
12. Imhof A., Ledergerber B., Gunthard H.F., et al. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring?. Clin Infect Dis 41 5 (2005) 721-728
13. Geddes R., Knight S., Moosa M.Y., et al. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 96 8 (2006) 722-724
14. Smith K.Y. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy. J Infect Dis 185 Suppl 2 (2002) S123-S127
15. Falco V., Crespo M., and Ribera E. Lactic acidosis related to nucleoside therapy in HIV-infected patients. Expert Opin Pharmacother 4 8 (2003) 1321-1329
16. Stacpoole P.W., Wright E.C., Baumgartner T.G., et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med 327 22 (1992) 1564-1569
17. Patel V., and Hedayati S.S. Lactic acidosis in an HIV-infected patient receiving highly active antiretroviral therapy. Nat Clin Pract Nephrol 2 2 (2006) 109-114 [quiz: 115]
18. Carter R.W., Singh J., Archambault C., et al. Severe lactic acidosis in association with reverse transcriptase inhibitors with potential response to L-carnitine in a pediatric HIV-positive patient. AIDS Patient Care STDS 18 3 (2004) 131-134
19. Claessens YE, Cariou A, Chiche JD, et al. L-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues. AIDS 10 2000;14(4):472-73.
20. Brinkman K., Vrouenraets S., Kauffmann R., et al. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 14 17 (2000) 2801-2802
21. Saint-Marc T., and Touraine J.L. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 13 15 (1999) 2188-2189
22. Lonergan J.T., Barber R.E., and Mathews W.C. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS 17 17 (2003) 2495-2499
23. Ogedegbe A.E., Thomas D.L., and Diehl A.M. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 3 6 (2003) 329-337
24. Brinkman K., Smeitink J.A., Romijn J.A., et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354 9184 (1999) 1112-1115
25. Carr A., and Cooper D.A. Adverse effects of antiretroviral therapy. Lancet 356 9239 (2000) 1423-1430
26. Montessori V., Press N., Harris M., et al. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 170 2 (2004) 229-238
27. Fagot J.P., Mockenhaupt M., Bouwes-Bavinck J.N., et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 15 14 (2001) 1843-1848
28. van Leth F., Phanuphak P., Ruxrungtham K., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363 9417 (2004) 1253-1263
29. Ofotokun I., and Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med 11 2 (2003) 55-59
30. Stern J.O., Robinson P.A., Love J., et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 34 Suppl 1 (2003) S21-S33
31. Lyons F., Hopkins S., Kelleher B., et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 7 4 (2006) 255-260
32. Clay P.G. The abacavir hypersensitivity reaction: a review. Clin Ther 24 10 (2002) 1502-1514
33. Phillips E.J. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?. Clin Infect Dis 43 1 (2006) 103-105
34. *5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359 9308 (2002) 727-732
35. Hetherington S., Hughes A.R., Mosteller M., et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359 9312 (2002) 1121-1122
36. Rauch A., Nolan D., Martin A., et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 43 1 (2006) 99-102
37. Phillips E.J., Sullivan J.R., Knowles S.R., et al. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 16 16 (2002) 2223-2225
38. Martin A.M., Nolan D., Gaudieri S., et al. Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. Pharmacogenomics 5 6 (2004) 643-655
39. Launay O., Roudiere L., Boukli N., et al. Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the Viramune-Zyrtec double-blind, placebo-controlled trial. Clin Infect Dis 38 8 (2004) e66-e72
40. Knobel H., Miro J.M., Domingo P., et al. Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J Acquir Immune Defic Syndr 28 1 (2001) 14-18
41. Gelato M.C. Insulin and carbohydrate dysregulation. Clin Infect Dis 36 Suppl 2 (2003) S91-S95
42. Currier J.S., Taylor A., Boyd F., et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 33 4 (2003) 506-512
43. Brown T.T., Cole S.R., Li X., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165 10 (2005) 1179-1184
44. Justman J.E., Benning L., Danoff A., et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 32 3 (2003) 298-302
45. Jones C.Y., Wilson I.B., Greenberg A.S., et al. Insulin resistance in HIV-infected men and women in the nutrition for healthy living cohort. J Acquir Immune Defic Syndr 40 2 (2005) 202-211
46. Howard A.A., Floris-Moore M., Arnsten J.H., et al. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis 40 10 (2005) 1492-1499
47. Behrens G., Dejam A., Schmidt H., et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13 10 (1999) F63-F70
48. Mauss S., Wolf E., and Jaeger H. Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors. Ann Intern Med 130 2 (1999) 162-163
49. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 6 (2002) 393-403
50. Hadigan C., Corcoran C., Basgoz N., et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 284 4 (2000) 472-477
51. van Wijk J.P., de Koning E.J., Cabezas M.C., et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 143 5 (2005) 337-346
52. Hadigan C., Yawetz S., Thomas A., et al. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 140 10 (2004) 786-794
53. Sutinen J., Hakkinen A.M., Westerbacka J., et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther 8 3 (2003) 199-207
54. Goldberg R.B., Kendall D.M., Deeg M.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 7 (2005) 1547-1554
55. Fonseca V., Rosenstock J., Patwardhan R., et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283 13 (2000) 1695-1702
56. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 9541 (2006) 1096-1105
57. Bosch J., Yusuf S., Gerstein H.C., et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 15 (2006) 1551-1562
58. Noor M.A., Parker R.A., O'Mara E., et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 18 16 (2004) 2137-2144
59. Dube M.P., Qian D., Edmondson-Melancon H., et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 35 4 (2002) 475-481
60. Yan Q., and Hruz P.W. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 40 4 (2005) 398-403
61. Carr A., Workman C., Smith D.E., et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288 2 (2002) 207-215
62. Smith D.E., Carr A., Law M., et al. Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study. AIDS 16 18 (2002) 2489-2491
63. Martinez E., Garcia-Viejo M.A., Blanco J.L., et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 31 5 (2000) 1266-1273
64. Thiebaut R., Dequae-Merchadou L., Ekouevi D.K., et al. Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-1999. HIV Med 2 2 (2001) 84-88
65. Purnell J.Q., Zambon A., Knopp R.H., et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14 1 (2000) 51-57
66. van der Valk M., Kastelein J.J., Murphy R.L., et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 15 18 (2001) 2407-2414
67. Young J., Weber R., Rickenbach M., et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 10 5 (2005) 585-591
68. Schmidt H.H., Behrens G., Genschel J., et al. Lipid evaluation in HIV-1-positive patients treated with protease inhibitors. Antivir Ther 4 3 (1999) 163-170
69. Behrens G., Schmidt H.H., Stoll M., et al. ApoE genotype and protease-inhibitor-associated hyperlipidaemia. Lancet 354 9172 (1999) 76
70. Dube M.P., Stein J.H., Aberg J.A., et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37 5 (2003) 613-627
71. Heart Protection Study Collaborative Group MB. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
72. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 15 (2004) 1495-1504
73. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol 44 3 (2004) 720-732
74. Henry K., Melroe H., Huebesch J., et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 352 9133 (1998) 1031-1032
75. Calza L., Colangeli V., Manfredi R., et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 19 10 (2005) 1103-1105
76. Calza L., Manfredi R., Colangeli V., et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 19 10 (2005) 1051-1058
77. Mobius U., Lubach-Ruitman M., Castro-Frenzel B., et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 39 2 (2005) 174-180
78. Cahn P.E., Gatell J.M., Squires K., et al. Atazanavir-a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic Ill) 3 3 (2004) 92-98
79. Barreiro P., Soriano V., Blanco F., et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 14 7 (2000) 807-812
80. De Luca A., Baldini F., Cingolani A., et al. Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study. AIDS 14 11 (2000) 1655-1656
81. Drechsler H., and Powderly W.G. Switching effective antiretroviral therapy: a review. Clin Infect Dis 35 10 (2002) 1219-1230
82. Viciana P, Alarcon A, Martin D, et al. Partial improvement in lipodystrophy after switching from HIV-1 protease inhibitors to efavirenz. Paper Presented at the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco (CA), January 30-February 2, 2000.
83. Bonnet E, Lepec R, Bluteau M, et al. Evaluation of lipodystrophy syndrome and lipid profile in HIV patients after switching from protease inhibitors to efavirenz. Presented at the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco (CA), January 30-February 2, 2000.
84. Bacchetti P., Gripshover B., Grunfeld C., et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 40 2 (2005) 121-131
85. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17 Suppl 1 (2003) S141-S148
86. Hadigan C., Meigs J.B., Wilson P.W., et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 36 7 (2003) 909-916
87. McComsey G.A., and Walker U.A. Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion 4 2-3 (2004) 111-118
88. Carr A., Workman C., Carey D., et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363 9407 (2004) 429-438
89. Slama L, Lanoy E, Valentin M, et al. Effect of pioglitazone on HIV-1 related lipoatrophy: a randomized double-blind placebo controlled trial (ANRS 113) with 130 patients. Presented at the 13th Conference on Retrovirus and Opportunistic Infections. Denver, February 5-8, 2006.
90. Sutinen J, Walker U, Sevastianova K, et al. Uridine supplementation increases subcutaneous fat in patients with HAART-associated lipodystrophy: a randomized, placebo-controlled trial. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin (Ireland), November 13-17, 2005.
91. McComsey G, Riordan M, Setzer B, et al. Effect of Nucleomaxx on fat and blood mitochondrial DNA in D4T-treated subjects with clinical lipoatrophy. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin (Ireland), November 13-17, 2005.
92. Mallon P.W., Miller J., Kovacic J.C., et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo-controlled study. AIDS 20 7 (2006) 1003-1010
93. Valantin M.A., Aubron-Olivier C., Ghosn J., et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 17 17 (2003) 2471-2477
94. Guaraldi G., Orlando G., De Fazio D., et al. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antivir Ther 10 6 (2005) 753-759
95. Moyle G.J., Sabin C.A., Cartledge J., et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20 16): (2006) 2043-2050
96. Martin A., Smith D.E., Carr A., et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18 7 (2004) 1029-1036
97. McComsey G.A., Ward D.J., Hessenthaler S.M., et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 38 2 (2004) 263-270
98. Lichtenstein K.A., Delaney K.M., Armon C., et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 32 1 (2003) 48-56
99. Gervasoni C., Ridolfo A.L., Trifiro G., et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 13 4 (1999) 465-471
100. Miller J., Carr A., Emery S., et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 4 3 (2003) 293-301
101. Saves M., Raffi F., Capeau J., et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 34 10 (2002) 1396-1405
102. Carter V.M., Hoy J.F., Bailey M., et al. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med 2 3 (2001) 174-180
103. Lean M.E., Han T.S., and Morrison C.E. Waist circumference as a measure for indicating need for weight management. BMJ 311 6998 (1995) 158-161
104. Smith B.A., Neidig J.L., Nickel J.T., et al. Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. AIDS 15 6 (2001) 693-701
105. Roubenoff R., McDermott A., Weiss L., et al. Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus. AIDS 13 2 (1999) 231-239
106. Roubenoff R., Weiss L., McDermott A., et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 13 11 (1999) 1373-1375
107. Wanke C., Gerrior J., Kantaros J., et al. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13 15 (1999) 2099-2103
108. Engelson E.S., Glesby M.J., Mendez D., et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 30 4 (2002) 379-391
109. Rebuffe-Scrive M., Marin P., and Bjorntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes 15 11 (1991) 791-795
110. Marin P., Holmang S., Jonsson L., et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 16 12 (1992) 991-997
111. Martinez E., Conget I., Lozano L., et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13 7 (1999) 805-810
112. Bozzette S.A., Ake C.F., Tam H.K., et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348 8 (2003) 702-710
113. Mary-Krause M., Cotte L., Simon A., et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17 17 (2003) 2479-2486
114. Holmberg S.D., Moorman A.C., Williamson J.M., et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360 9347 (2002) 1747-1748
115. Friis-Moller N., Weber R., Reiss P., et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17 8 (2003) 1179-1193
116. Friis-Moller N, Reiss P, El-Sadr W, et al. Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D study. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver (CO), February 5-8, 2006.
117. Currier J.S., Kendall M.A., Zackin R., et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 19 9 (2005) 927-933
118. Depairon M., Chessex S., Sudre P., et al. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS 15 3 (2001) 329-334
119. Hsue P.Y., Lo J.C., Franklin A., et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109 13 (2004) 1603-1608
120. Blanco J.J., Garcia I.S., Cerezo J.G., et al. Endothelial function in HIV-infected patients with low or mild cardiovascular risk. J Antimicrob Chemother 58 1 (2006) 133-139
121. Maggi P., Serio G., Epifani G., et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 14 16 (2000) F123-F128
122. Twu C., Liu N.Q., Popik W., et al. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. Proc Natl Acad Sci U S A 99 22 (2002) 14386-14391
123. van Wijk J.P., de Koning E.J., Cabezas M.C., et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 47 6 (2006) 1117-1123
124. Stein J.H. Cardiovascular risk in patients with human immunodeficiency virus infection: incomplete data. J Am Coll Cardiol 47 6 (2006) 1124-1125